News
NGEN
3.565
-3.91%
-0.145
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
TipRanks · 3h ago
Weekly Report: what happened at NGEN last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at NGEN last week (0427-0501)?
Weekly Report · 05/04 09:06
NervGen Pharma (NGEN) Gets a Buy from Stifel Nicolaus
TipRanks · 04/28 14:35
HC Wainwright & Co. Initiates Coverage of NervGen Pharma (NGEN) with Buy Recommendation
NASDAQ · 04/28 00:04
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
TipRanks · 04/27 23:23
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 04/27 12:08
NervGen Pharma Initiated at Buy by HC Wainwright & Co.
Dow Jones · 04/27 11:48
NervGen Pharma Price Target Announced at $18.00/Share by HC Wainwright & Co.
Dow Jones · 04/27 11:48
NervGen Pharma Names Keith Vendola Chief Financial Officer
Dow Jones · 04/27 11:47
HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18
Benzinga · 04/27 11:38
NervGen Pharma Appoints Keith Vendola CFO, Effective Immediately
Benzinga · 04/27 11:37
NervGen Pharma appoints Keith Vendola as CFO
PUBT · 04/27 11:32
Press Release: NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
Dow Jones · 04/27 11:30
NervGen Pharma initiated with a Buy at H.C. Wainwright
TipRanks · 04/27 10:13
NERVGEN PHARMA CORP. <NGEN.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $18
Reuters · 04/27 10:12
Weekly Report: what happened at NGEN last week (0420-0424)?
Weekly Report · 04/27 09:06
Analysts Offer Insights on Healthcare Companies: NervGen Pharma (NGEN), Atai Beckley N.V. (ATAI) and Journey Medical Corp (DERM)
TipRanks · 04/24 08:30
Weekly Report: what happened at NGEN last week (0413-0417)?
Weekly Report · 04/20 09:05
NervGen Pharma initiated with a Buy at Lucid Capital
TipRanks · 04/15 10:11
More
Webull provides a variety of real-time NGEN stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.